St.Anna
- Address
- Bogardeind 2, 5664 EH Geldrop, The Netherlands
Gastrointestinal Cancer Research
At St.Anna in Gelderland, the Gynaecology department is involved in digestive system disease and neoplasm research focused on gastric cancer and locally advanced rectal cancer. These studies are designed to compare treatment approaches, improve survival, and refine care for patients with advanced disease.
- Resectable gastric adenocarcinoma
- Locally advanced rectal cancer
- Peritoneal dissemination in stomach cancer
Research here includes evaluating surgery-based strategies, preoperative treatment combinations, and approaches that may improve long-term outcomes for people with complex gastrointestinal cancers.
Breast Cancer Studies
The site is also active in neoplasm research for breast cancer, including triple negative breast cancer and hormone receptor-positive metastatic breast cancer. The trials aim to improve treatment effectiveness, support better response rates, and explore smarter ways to tailor therapy.
- HER2-positive breast cancer
- Triple negative breast cancer
- HR+/HER2- metastatic breast cancer
These studies examine newer treatment strategies, including adding targeted or immune-based therapies to standard care, with the goal of improving outcomes while keeping treatment as effective and manageable as possible.
Women’s Health and HPV-Related Disease
Clinical research at St.Anna also covers female urogenital diseases, with attention to vulvar High-Grade Squamous Intraepithelial Lesion. The purpose of this work is to reduce recurrence and strengthen prevention after treatment.
- Vulvar HSIL
- HPV-related disease
These trials are focused on preventive care, especially evaluating whether vaccination after treatment can help lower the chance of the condition returning.
Hematology and Blood Cancer Research
The site contributes to multiple myeloma research within neoplasm and therapeutics studies. The main goal is to understand whether treatment can be adjusted to maintain disease control while giving patients more flexibility in ongoing care.
- Multiple myeloma
This area includes comparing continuous treatment with treatment pauses and restart strategies, helping clarify how best to balance effectiveness and quality of life in blood cancer care.
Cardiovascular and Surgical Prevention Research
Another important focus is cardiovascular disease research centered on venous thromboembolism prevention after major joint surgery. These studies aim to improve safety by matching prevention strategies to patient risk.
- Venous thromboembolism
- Thrombosis prevention after hip and knee replacement
The research explores whether standard, reduced, or intensified prevention approaches can best protect patients from blood clots while minimizing bleeding complications.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 50 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 49 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in St.Anna
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Adjuvant Pembrolizumab Versus Capecitabine or Olaparib in Patients with Early-Stage Triple-Negative Breast Cancer with Residual Disease Following Neoadjuvant Therapy | Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | Phase III | Recruiting | Jul 2026 | — |
IMP list
lock Showing 1 of 50 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Oxaliplatin | 4 | Unknown | 2017-09-28 | 2026-03-11 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.